Health and Healthcare
Gilead Sciences... The Beat Goes On (GILD)
Published:
Last Updated:
Gilead Sciences, Inc. (NASDAQ: GILD) posted results after the close today. Its Q1 revenues surged to $1.26 billion and non-GAAP earnings was $522.1 million, or $0.54 EPS. First Call had estimates at $0.48 EPS on $1.22 billion in revenues.
Gilead had cash and equivalents of $2.59 billion and generated $577.1 million of operating cash flows, which was offset by repurchases of $815.8 million of common stock. As of March 31, 2008, Gilead had approximately $2.15 billion remaining under this share repurchase program.
Its own product sales accounted for $1.14 Billion in Q1 revenues, up 36% because of a strong HIV franchise led by the continued strong uptake of Atripla.
Shares closed up 1.4% at $51.80 in normal trading, and shares rose 2.8% to $53.26 in after-hours trading. Its 52-week trading had been $35.22 to $53.20. Despite a 10-fold to 20-fold gain this decade, the company just keeps doing better and better.
Jon C. Ogg
April 16, 2008
Jon Ogg produces the Special Situation Investing Newsletter. He can be reached at [email protected] and he does not own securities in the companies he covers.
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.